- Report
- May 2026
- 200 Pages
Global
From €4297EUR$4,750USD£3,680GBP
- Report
- August 2025
- 188 Pages
Global
From €4071EUR$4,500USD£3,486GBP
- Report
- July 2026
- 388 Pages
Global
From €5292EUR$5,850USD£4,532GBP
- Report
- May 2026
- 100 Pages
Global
From €2442EUR$2,699USD£2,091GBP
- Report
- January 2026
- 180 Pages
Global
From €4071EUR$4,500USD£3,486GBP
- Report
- April 2026
- 140 Pages
Global
From €3573EUR$3,950USD£3,060GBP
- Report
- August 2025
- 156 Pages
Global
From €3256EUR$3,599USD£2,788GBP
- Clinical Trials
- December 2025
- 219 Pages
Global
From €3121EUR$3,450USD£2,673GBP
- Clinical Trials
- December 2025
- 636 Pages
Global
From €3121EUR$3,450USD£2,673GBP
- Clinical Trials
- August 2025
- 2906 Pages
Global
From €3121EUR$3,450USD£2,673GBP
- Report
- April 2026
- 160 Pages
Global
From €3003EUR$3,320USD£2,572GBP
€3754EUR$4,150USD£3,215GBP
- Report
- April 2026
- 160 Pages
Global
From €3003EUR$3,320USD£2,572GBP
€3754EUR$4,150USD£3,215GBP
- Report
- April 2026
- 160 Pages
Global
From €3003EUR$3,320USD£2,572GBP
€3754EUR$4,150USD£3,215GBP
- Report
- April 2026
- 160 Pages
Global
From €3003EUR$3,320USD£2,572GBP
€3754EUR$4,150USD£3,215GBP
- Report
- April 2026
- 160 Pages
Global
From €3003EUR$3,320USD£2,572GBP
€3754EUR$4,150USD£3,215GBP
- Report
- April 2026
- 160 Pages
Global
From €3003EUR$3,320USD£2,572GBP
€3754EUR$4,150USD£3,215GBP
- Report
- April 2026
- 160 Pages
Global
From €3003EUR$3,320USD£2,572GBP
€3754EUR$4,150USD£3,215GBP
- Report
- April 2026
- 160 Pages
Global
From €3003EUR$3,320USD£2,572GBP
€3754EUR$4,150USD£3,215GBP
- Report
- April 2026
- 160 Pages
Global
From €3003EUR$3,320USD£2,572GBP
€3754EUR$4,150USD£3,215GBP
- Report
- April 2026
- 160 Pages
Global
From €3003EUR$3,320USD£2,572GBP
€3754EUR$4,150USD£3,215GBP

The Gastrointestinal Drugs market is a sector of the pharmaceutical industry that focuses on the development and production of drugs used to treat diseases and disorders of the gastrointestinal tract. These drugs are used to treat conditions such as irritable bowel syndrome, Crohn's disease, ulcerative colitis, and gastroesophageal reflux disease. Commonly prescribed drugs include antacids, proton pump inhibitors, and H2 receptor antagonists.
The Gastrointestinal Drugs market is highly competitive, with many large pharmaceutical companies vying for market share. Some of the major players in the market include Pfizer, GlaxoSmithKline, Merck & Co., AstraZeneca, and Novartis. These companies are constantly developing new drugs and treatments to meet the needs of patients. Show Less Read more